Hong Kong Stock Movement | ZHAOKE OPHTH-B (06622) Surged Over 8% in Afternoon Session as Three Core Drugs Enter NDA Stage, Recently Reached Strategic Partnership with PT Ferron

Stock News

Sep 01

ZHAOKE OPHTH-B (06622) surged over 8% in the afternoon session. As of press time, the stock was up 7.14% to HK$3.75, with a turnover of HK$11.603 million.

On the news front, ZHAOKE OPHTH-B released its interim results, reporting revenue of RMB 15.803 million, down 68.25% year-over-year; net loss was RMB 117 million, up 53.85% year-over-year.

Notably, in the first half of 2025, three core drug candidates of ZHAOKE OPHTH-B - Atropine Sulfate Eye Drops, Cyclosporine Ophthalmic Gel, and Bevacizumab Intravitreal Injection - have entered the New Drug Application (NDA) stage. The company expects to achieve the important goal of commercializing a cumulative total of 12 drugs by the end of 2026.

ZHAOKE OPHTH-B previously announced that the company has signed a distribution and supply agreement with leading Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals for the Indonesian market regarding its core product: Atropine Sulfate Eye Drops (NVK002) for slowing myopia progression in children and adolescents.

Under the terms of the agreement, ZHAOKE OPHTH-B grants PT Ferron exclusive rights to import, promote, distribute, market and sell the product in Indonesia. ZHAOKE OPHTH-B will receive an upfront payment and may receive additional milestone payments based on certain achievements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1194509740"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194509740\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194509740?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-01 15:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194509740","market":"sh","top_or_hot":-1,"title":"Hong Kong Stock Movement | ZHAOKE OPHTH-B (06622) Surged Over 8% in Afternoon Session as Three Core Drugs Enter NDA Stage, Recently Reached Strategic Partnership with PT Ferron","media":"Stock News","content":"<p>ZHAOKE OPHTH-B (06622) surged over 8% in the afternoon session. As of press time, the stock was up 7.14% to HK$3.75, with a turnover of HK$11.603 million.</p>\n<p>On the news front, ZHAOKE OPHTH-B released its interim results, reporting revenue of RMB 15.803 million, down 68.25% year-over-year; net loss was RMB 117 million, up 53.85% year-over-year.</p>\n<p>Notably, in the first half of 2025, three core drug candidates of ZHAOKE OPHTH-B - Atropine Sulfate Eye Drops, Cyclosporine Ophthalmic Gel, and Bevacizumab Intravitreal Injection - have entered the New Drug Application (NDA) stage. The company expects to achieve the important goal of commercializing a cumulative total of 12 drugs by the end of 2026.</p>\n<p>ZHAOKE OPHTH-B previously announced that the company has signed a distribution and supply agreement with leading Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals for the Indonesian market regarding its core product: Atropine Sulfate Eye Drops (NVK002) for slowing myopia progression in children and adolescents.</p>\n<p>Under the terms of the agreement, ZHAOKE OPHTH-B grants PT Ferron exclusive rights to import, promote, distribute, market and sell the product in Indonesia. ZHAOKE OPHTH-B will receive an upfront payment and may receive additional milestone payments based on certain achievements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | ZHAOKE OPHTH-B (06622) Surged Over 8% in Afternoon Session as Three Core Drugs Enter NDA Stage, Recently Reached Strategic Partnership with PT Ferron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | ZHAOKE OPHTH-B (06622) Surged Over 8% in Afternoon Session as Three Core Drugs Enter NDA Stage, Recently Reached Strategic Partnership with PT Ferron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-01 15:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZHAOKE OPHTH-B (06622) surged over 8% in the afternoon session. As of press time, the stock was up 7.14% to HK$3.75, with a turnover of HK$11.603 million.</p>\n<p>On the news front, ZHAOKE OPHTH-B released its interim results, reporting revenue of RMB 15.803 million, down 68.25% year-over-year; net loss was RMB 117 million, up 53.85% year-over-year.</p>\n<p>Notably, in the first half of 2025, three core drug candidates of ZHAOKE OPHTH-B - Atropine Sulfate Eye Drops, Cyclosporine Ophthalmic Gel, and Bevacizumab Intravitreal Injection - have entered the New Drug Application (NDA) stage. The company expects to achieve the important goal of commercializing a cumulative total of 12 drugs by the end of 2026.</p>\n<p>ZHAOKE OPHTH-B previously announced that the company has signed a distribution and supply agreement with leading Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals for the Indonesian market regarding its core product: Atropine Sulfate Eye Drops (NVK002) for slowing myopia progression in children and adolescents.</p>\n<p>Under the terms of the agreement, ZHAOKE OPHTH-B grants PT Ferron exclusive rights to import, promote, distribute, market and sell the product in Indonesia. ZHAOKE OPHTH-B will receive an upfront payment and may receive additional milestone payments based on certain achievements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"","article_id":"1194509740","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194509740","pubTimestamp":1756712299,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ZHAOKE OPHTH-B (06622) surged over 8% in the afternoon session. As of press time, the stock was up 7.14% to HK$3.75, with a turnover of HK$11.603 million. On the news front, ZHAOKE OPHTH-B released...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1587":"次新股","BK1574":"生物医药B类股","PT":"品钛","06622":"兆科眼科-B","BK1583":"高瓴概念","BK4166":"消费信贷","BK1191":"制药"},"translate_title":"港股动向|兆科眼科-B(06622)午后大涨超8%，三款核心药物进入NDA阶段，近日与PT Ferron达成战略合作伙伴关系","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1,"PT":1},"content_text":"ZHAOKE OPHTH-B (06622) surged over 8% in the afternoon session. As of press time, the stock was up 7.14% to HK$3.75, with a turnover of HK$11.603 million.\nOn the news front, ZHAOKE OPHTH-B released its interim results, reporting revenue of RMB 15.803 million, down 68.25% year-over-year; net loss was RMB 117 million, up 53.85% year-over-year.\nNotably, in the first half of 2025, three core drug candidates of ZHAOKE OPHTH-B - Atropine Sulfate Eye Drops, Cyclosporine Ophthalmic Gel, and Bevacizumab Intravitreal Injection - have entered the New Drug Application (NDA) stage. The company expects to achieve the important goal of commercializing a cumulative total of 12 drugs by the end of 2026.\nZHAOKE OPHTH-B previously announced that the company has signed a distribution and supply agreement with leading Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals for the Indonesian market regarding its core product: Atropine Sulfate Eye Drops (NVK002) for slowing myopia progression in children and adolescents.\nUnder the terms of the agreement, ZHAOKE OPHTH-B grants PT Ferron exclusive rights to import, promote, distribute, market and sell the product in Indonesia. ZHAOKE OPHTH-B will receive an upfront payment and may receive additional milestone payments based on certain achievements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}